Peevee Pharma And Feeds Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 18-06-2024
- Paid Up Capital ₹ 2.50 M
as on 18-06-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.29 M
as on 18-06-2024
- Satisfied Charges ₹ 3.00 M
as on 18-06-2024
- Revenue 2.12%
(FY 2023)
- Profit -20.66%
(FY 2023)
- Ebitda -0.91%
(FY 2023)
- Net Worth 11.55%
(FY 2023)
- Total Assets 11.93%
(FY 2023)
About Peevee Pharma And Feeds
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹4.29 M. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Venkata Krishnarao, Paruchuri Vidyullatha, and Sunil Veeramachaneni serve as directors at the Company.
- CIN/LLPIN
U24239AP1995PLC019615
- Company No.
019615
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Mar 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Vijayawada, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Peevee Pharma And Feeds?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Krishnarao  | Managing Director | 01-Apr-2005 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Paruchuri Vidyullatha | Director | 30-Sep-2000 | Current |
| Sunil Veeramachaneni | Director | 13-Sep-2018 | Current |
Financial Performance of Peevee Pharma And Feeds.
Peevee Pharma And Feeds Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.12% increase. The company also saw a substantial fall in profitability, with a 20.66% decrease in profit. The company's net worth Soared by an impressive increase of 11.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Peevee Pharma And Feeds?
In 2023, Peevee Pharma And Feeds had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 13 Mar 2019 | ₹1.89 M | Open |
State Bank Of India Creation Date: 08 Sep 2017 | ₹2.40 M | Open |
State Bank Of India Creation Date: 28 Jan 2004 | ₹1.50 M | Satisfied |
How Many Employees Work at Peevee Pharma And Feeds?
Unlock and access historical data on people associated with Peevee Pharma And Feeds, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Peevee Pharma And Feeds, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Peevee Pharma And Feeds's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
